Conclusions:
The GEP provides valuable prognostic information and improves identification of highrisk melanomas when used together with the AJCC online prediction tool. ( J Am Acad Dermatol 2017;76:818-25.)
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Clinical staging of primary cutaneous melanoma (CM) is important for evaluating an individual patient's conditional risk of recurrence, as stage guides decisionmaking for patient surveillance and treatment. The American Joint Committee on Cancer (AJCC) melanoma guidelines recommend using tumor thickness, ulceration, sentinel lymph node (SLN) status, and mitotic rate for stratifying patients at low and high risk. [1] [2] [3] [4] [5] The impact of stage-based stratification of risk, as reflected in the current National Comprehensive Cancer Network guidelines, is that imaging is not routinely recommended for patients with stage I and IIA disease or asymptomatic patients. 6 Yet, because of the prevalence of patients at early stage given a diagnosis each year, this lower risk group represents two thirds of the patients who ultimately die of melanoma each year. 5, 7 The impact of contemporary immunotherapy and viral therapies on metastatic disease detected at the time of lower tumor burden has been reported, suggesting that a high intensity follow-up plan for patients with high-risk melanoma may lead to earlier detection of metastatic disease when therapeutic efficacy can be enhanced. [8] [9] [10] Thus, improving the accuracy of identifying patients with high-risk disease not predicted by AJCC stage alone represents an important actionable goal. A recently validated gene expression profile (GEP) test (DecisionDxMelanoma, Castle Biosciences, Inc, Friendswood, TX) with prognostic accuracy for identifying highrisk, early-stage melanomas evaluates 31 genetic targets to more accurately identify high-risk tumor biology compared with clinical or pathologic assessment alone. 11, 12 The test measures gene expression levels from primary melanoma tumors to provide a binary classification of low (class 1 with 5-year distant metastasis-free survival [DMFS] of 91%) or high (class 2 with 5-year DMFS of 57%) risk for metastasis. Performance of the GEP test has been reported in 2 multicenter validation studies, and was shown to be an accurate prognosticator of survival independent of AJCC stage. 11, 12 The current study was designed to compare the accuracy of the GEP prognostic assay with the accuracy of risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool. The AJCC prognostic tool is frequently used by clinicians to attain estimates of 1-, 2-, 5-, and 10-year survival based on clinical data, which in turn directs appropriate patient treatment. 13 The study includes 205 patients with previously reported stage I and II melanoma and sufficient clinical data to obtain 5-year survival predictions from the AJCC tool, and compares the AJCC and GEP predictions to determine whether gene expression profiling, used in combination with current clinical factors, enhances identification of patients with highrisk melanoma.
METHODS

Sample and clinical data collection
Archived formalin-fixed, paraffin-embedded primary CM tissue and associated deidentified clinical data were collected after institutional review board approval from 6 US centers and processed as previously described. 11 Inclusion in the study required biopsy-confirmed stage I or II CM originally diagnosed between 1998 and 2009. Patients younger than 18 years or previously given a diagnosis of another malignant tumor type were excluded. An earlier censor (May 2013) of this cohort was previously reported 12 ; outcomes were updated with a censor date of July 2015. All samples with successful GEP classification were reviewed for clinical chart and pathology report data. Radial basis machine predictive modeling with JMP Genomics SAS-based software (SAS, Cary, NC) was used to evaluate the gene expression of 28 prognostic and 3 control genes providing a binary classification of CM tumors as class 1 (low risk of metastasis) or class 2 (high risk of metastasis) with a probability score of 0.50 (on a scale of 0.0-1.0) as the cut point between class 1 and class 2. Normal versus reduced confidence regions of the linear score were previously established using median probability score and 1SD from the median, and delineate a normal confidence: (1) class 1A group (median probability score 0.268; SD 0.144), and (2) class 2B group (median probability score 0.726; SD 0.138). Validation set cases falling outside those SD ranges were classified as reduced confidence class 1B or class 2A samples. Of note, samples with probability scores in the reduced confidence range were processed with technical success and yielded valid class predictions. 
Study aims and statistical analysis
The primary aim for the study was the comparison of the GEP-based classification with the AJCC online prediction tool as an independent predictor of recurrence-free survival (RFS) (recurrence defined as any regional or distant metastasis detected after determination of AJCC stage), DMFS (defined as a distant metastasis detected beyond the regional basin), or overall survival (OS) (defined as death as a result of any cause). The secondary aim of the study was evaluation of the utility of the 2 tools used in combination to better identify patients at a high risk of metastatic disease. All analyses comparing the prognostic tools were performed with a binary GEP classification of class 1 versus class 2. To this end, GEP classification was combined with the AJCC prediction of risk to produce 4 subgroups: class 1/ AJCC low risk, class 1/AJCC high risk, class 2/AJCC low risk, and class 2/AJCC high risk. Kaplan-Meier analysis and Cox proportional hazards survival analysis were performed using WinSTAT for Microsoft Excel version 2012.1 (R. Fitch Software, Cambridge, MA).
RESULTS
Demographics of the study cohort
A total of 205 primary melanoma tumors collected from 6 US centers were evaluated during the study (Supplementary Table I 
Independent and combined GEP and AJCC prediction of risk
Sensitivity and specificity of each of the prognostic tools (GEP, AJCC 79%, AJCC 68%), both independently and in combination, was also determined (Table I and Supplementary Table II [available  at http://www.jaad.org]). Using the binary class 1 versus class 2 GEP classification of risk, the analysis revealed a significantly higher sensitivity, but lower specificity, for the GEP test compared with the AJCC predictor, with both the 79% and 68% cutoff scores. As shown in Table I , the sensitivities of the GEP test to accurately identify as class 2 patients who experienced recurrences, distant metastasis, and melanoma-specific deaths were 82%, 81%, and 78%, respectively. Comparably, the AJCC tool using the 79% cutoff achieved sensitivities of 70%, 69%, and 60%, respectively, for each end point; using the recurrence-free survival SLN:
sentinel lymph node 68% cutoff achieved sensitivities of 36%, 40%, and 28%, respectively. Results indicate a significant further increase in sensitivity when the AJCC and GEP tests were considered collectively. The sensitivities of the combined GEP and AJCC 79% tools to accurately identify as patients at high risk who experienced recurrences, distant metastasis, and melanoma-specific deaths were 90%, 88%, and 82%, respectively, with specificities of 71%, 63%, and 62%, respectively. Cox univariate analysis of RFS, DMFS, and OS resulted in a statistically significant risk assessment for all 3 predictors (Supplementary Table III; available at http://www.jaad.org). Multivariate Cox regression (Table II) comparing GEP with each of the AJCC tools (GEP vs AJCC 79% cutoff or GEP vs AJCC 68% cutoff) indicates that the GEP predictor is more significantly associated with the end points of distant metastasis and death than the binary classification based on the AJCC predicted risk. Direct comparison of the GEP with the AJCC online predictor, using a cutoff of 79% to stratify high and low Survival outcomes for combined GEP and AJCC prediction of risk Kaplan-Meier analysis of cases with concordant low-or high-risk predictions from both tools resulted in the highest and lowest 5-year survival for both end points, with RFS, DMFS, and OS of 95%, 96%, and 96%, respectively, for class 1/AJCC low-risk cases, compared with 17%, 39%, and 44%, respectively, for class 2/AJCC high-risk cases (Fig 2) . Thirteen class 1/ AJCC high-risk cases were identified with 5-year RFS, DMFS, and OS of 75%, 92% and 83%, respectively. RFS, DMFS, and OS of 62%, 76%, and 71%, respectively were seen in class 2/AJCC low-risk cases (n = 30).
The pie charts in Fig 2 show the concordant and discordant GEP and AJCC predictions of risk for those cases that experienced a recurrence, distant metastasis, or death. Of clinical significance, 82% of recurrences, 81% of distant metastases, and 78% of deaths were identified as high-risk class 2, compared with 69%, 69%, and 60%, respectively, identified as high risk by AJCC. Combining the AJCC predictor with the GEP resulted in accurate identification of 90% of cases with recurrences, 88% of distant metastases, and 82% of deaths.
Analysis of cases with discordant prediction of risk
Of the 205 cases included in the study, 43 (21%) resulted in discordant predicted outcomes when comparing the GEP and AJCC 79% prognostic tools. As shown in Table III , 30 cases were predicted to be high-risk class 2 by the GEP and low risk by the AJCC predictor, whereas 13 cases were low-risk class 1 and high risk according to the AJCC tool. Fourteen (46%) class 2/AJCC low-risk cases experienced an outcome event: 13 (43%; median Breslow 1.5 mm; 2 with ulceration) developed regional or distant metastasis, 9 (30%) developed distant metastasis, and 11 (37%) resulted in death. Comparably, 5 (38%) class 1/AJCC high-risk cases experienced an outcome event: 5 (38%; median Breslow 1.7 mm; 3 ulcerated) with a regional or distant metastatic event, 3 (23%) with distant metastasis, and 2 (15%) resulted in death. Notably, of these class 1/AJCC high-risk cases, 4 of the regional or distant metastatic events, 3 with distant metastasis, and 1 death occurred in cases called class 1B, with probability scores falling within the reduced confidence range (Table III) . Of clinical significance, the cohort of cases that experienced adverse events and were identified as low risk according to the AJCC predictor, but high-risk class 2 according to GEP, included 11 stage IA, IB, and IIA cases.
DISCUSSION
The AJCC TNM staging system for melanoma guides clinical decisions regarding consideration of referral for SLN mapping, frequency and intensity of surveillance, consideration of adjuvant therapy, and clinical trial opportunities. Because patients at stage I and II comprise the vast majority of the melanoma diagnoses, more than 2 of 3 deaths related to CM occur in this group of patients initially given a diagnosis of node-negative disease (AJCC stages I-II). The most recent update to the AJCC melanoma staging criteria (v7, 2010) recommends discussion of the utility of SLN biopsy with any patient presenting with ulceration or mitotic rate greater than or equal to 1/mm 2 (stage IB-II). 4 As a result, the procedure is commonly performed in thin melanomas with a positive SLN yield of less than 5%. Also, fewer than 20% of patients who are SLNpositive experience subsequent distant metastatic disease. [14] [15] [16] [17] [18] [19] The current study was designed to compare independent prediction of risk by the GEP or the AJCC Individualized Melanoma Patient Outcome Prediction Tool, and the potential utility of combining the results of the 2 prognosticators. Our findings identified the GEP test as a strong independent predictor of risk, and Cox univariate and multivariate regression analysis indicated a highly significant association between the class 2 gene signature and increased risk of recurrence and death. As reported, combining results from the 2 tools enhanced sensitivity, reflecting a more accurate identification of patients with high-risk stage I and II melanoma. Although increased sensitivity is achieved with concurrent loss of specificity, for each of the end points analyzed gains in sensitivity when combining the GEP with AJCC tools outweigh the reduction in specificity (Table I) .
In summary, this report shows that the GEP test, when used in combination with AJCC, can improve identification of those patients with stage I and II CM and a high risk of developing recurrence, metastatic disease, or both. Importantly, 11 of the 13 patients predicted as low risk by the AJCC tool but classified as high risk (class 2) by the GEP were stage I or IIA. These patients would traditionally be treated with less intensive surveillance plans and no opportunity for adjuvant intervention to prevent recurrence. With the development of novel and effective therapeutic advances with improved toxicity profiles, including the recent approval of ipilimumab for patients with stage III disease and other agents currently under investigation, incorporation of the GEP test to current staging methods may offer the ability to identify the majority of patients at risk for metastasis and death who could potentially benefit from more aggressive and early therapeutic intervention. 10, 20 Notably, improved efficacy has been observed for several melanoma therapies when administered to patients with lower tumor burden. [8] [9] [10] Conversely, GEP low-risk (class 1) classification can provide an opportunity to decrease follow-up intensity and avoid overtreatment of patients with less biologically aggressive tumors. 21 Combining GEP-based classification with AJCC staging may help identify the majority of patients who would benefit from increased clinical and imaging-based surveillance, to identify metastatic disease earlier and ultimately administer the most effective therapies developed to date to improve patient outcomes. AJCC, American Joint Committee on Cancer. *1Aeclass 1 with probability score 0-0.409. y 1Beclass 1 with probability score 0.41-0.5. 
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